Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
AarogyaAI is a software-as-a-service platform that utilizes artificial intelligence to identify drug-resistant tuberculosis (DR-TB) within hours. Our goal is to provide rapid and precise diagnoses of DR-TB, ensuring that patients receive the most effective drug combinations for their treatment without delay. Tuberculosis is responsible for more fatalities annually than AIDS, largely because the 19 available anti-TB medications do not work for all patients, leading to uncertainty among doctors regarding the appropriate treatment options. Consequently, even though tuberculosis is treatable, a delayed diagnosis of drug-resistant forms can result in patients remaining on ineffective medications for as long as seven years. By diagnosing drug-resistant tuberculosis swiftly, we enable prompt and appropriate treatment prescriptions. Patients upload a DNA sequence to our platform, and our advanced machine learning algorithm processes this data to generate a detailed report on drug susceptibility status, allowing healthcare providers to make informed decisions about treatment. This innovative approach not only enhances patient outcomes but also aims to reduce the overall burden of tuberculosis on healthcare systems.
Description
PharmaPendium serves as a robust platform that grants users access to a wide array of FDA and EMA drug approval documents, encompassing essential aspects like pharmacokinetics, pharmacodynamics, and safety evaluations. This resource delivers in-depth insights into drug-drug interactions, side effects, and outcomes from clinical studies, thereby empowering stakeholders to make well-informed decisions during the drug development process and when making regulatory submissions. Its rich database aids researchers and healthcare practitioners in assessing both the efficacy and safety of medications, playing a pivotal role in the progression of pharmaceutical research and enhancing patient care. Users can explore historical regulatory submissions and leverage past precedents to better understand and anticipate agency requirements. The interface allows for a seamless transition from tabular data to dynamic charts, graphs, and other visual tools, making it easier to analyze and interpret findings. Additionally, users can search for information related to adverse events (MedDRA), therapeutic targets, drug indications, and endpoints utilizing standardized data. Result pages effectively connect preclinical research with clinical applications, facilitating a comprehensive understanding of the drug development landscape. Overall, this platform not only streamlines the research process but also fosters collaboration and knowledge-sharing among industry professionals.
API Access
Has API
No
API Access
Has API
No
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
No
Webinars
No
Live Training (Online)
No
In Person
No
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
Yes
In Person
Yes
Vendor Details
Company Name
AarogyaAI
Country
India
Website
aarogya.ai/
Vendor Details
Company Name
Elsevier
Founded
1880
Country
Netherlands
Website
www.elsevier.com/products/pharmapendium